The civic record
Read. Follow. Verify.Louisiana House Bill 277 requires prescription drug marketing materials given to doctors to include pricing and generic availability
Last action · March 9, 2026: Read by title, under the rules, referred to the Committee on Health and Welfare.Sponsor: Dennis Bamburg
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
DRUGS/PRESCRIPTION: Requires educational or marketing materials for prescription drugs directed to healthcare providers to include price information (OR SEE FISC NOTE GF EX)
Prescription drug marketers and pharmaceutical representatives must disclose wholesale costs and alternative generic medications directly to doctors, altering how medication information is distributed to medical practices in the state.
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Healthcare providers
Prescription drug marketers and manufacturers
Entities providing educational or marketing materials to doctors must include specific pricing information, preparation dates, and generic alternatives, or face penalties under consumer protection laws.
Key Facts
- Requires any person providing educational or marketing materials for a prescription drug to a healthcare provider to include price information and whether a generic or biosimilar drug is available for the same disease state.
- Mandated price information must include the date the materials were prepared.
- Mandated price information must include the average wholesale acquisition cost of a 30-day supply of the drug.
- For drugs designed for therapy lasting less than 30 days, materials must state the proposed duration and average wholesale price for that period.
Show all 5 facts
- Violations of this requirement constitute a prohibited practice under the Unfair Trade Practices and Consumer Protection Law.
Frequently Asked Questions
Who must include price information under House Bill 277?
What specific pricing details must be included in the materials?
What happens if someone violates these disclosure requirements?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in House committee.
Procedural history
4 actions- Mar 9, 2026HouseIntroducedRead by title, under the rules, referred to the Committee on Health and Welfare.
- Feb 27, 2026HouseFirst appeared in the Interim Calendar on 2/27/2026.
- Feb 23, 2026HousePrefiled.
- Feb 23, 2026HouseCommitteeUnder the rules, provisionally referred to the Committee on Health and Welfare.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Connected Entities
Sources
www.legis.la.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 50)
- Controversy40Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz35Current news / social attention level
Publisher tools